SAN DIEGO—(BUSINESS WIRE)—April 18, 2007—ACADIA PharmaceuticalsInc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders, today announced thatit will present at the following investor conferences:
- The 7th Annual Fortis Bank Biotechnology Conference onWednesday, April 25, 2007 at 10:30 a.m. Western European Timeat the Four Seasons Hotel London, in London, England.
- The Deutsche Bank 32nd Annual Healthcare Conference onWednesday, May 2, 2007 at 9:45 a.m. Eastern Time at theRenaissance Mayflower Hotel in Washington, D.C.
- The Acumen BioFin Rodman & Renshaw 4th Annual GlobalHealthcare Conference on Monday, May 14, 2007 at 10:05 a.m.Central European Time at Le Meridien Beach Plaza Hotel inMonte Carlo, Monaco.
Live webcasts of these presentations will be accessible on thecompany's website, www.acadia-pharm.com, under the investors sectionand an archived recording will be available on the website for twoweeks following the presentation.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders. ACADIA currently hasfive clinical programs as well as a portfolio of preclinical anddiscovery assets directed at large unmet medical needs, includingschizophrenia, Parkinson's disease psychosis, sleep maintenanceinsomnia, and neuropathic pain. All of the drug candidates in ACADIA'sproduct pipeline emanate from discoveries made using its proprietarydrug discovery platform. ACADIA's corporate headquarters is located inSan Diego, California and it maintains research and developmentoperations in both San Diego and Malmo, Sweden.
CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief FinancialOfficer
858-558-2871
SOURCE: ACADIA Pharmaceuticals Inc.